John Feller, MD, presented “Current and Emerging Role of Radiogenomics in Risk Assessment” during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in October 2020.
How to cite: Feller, John. “Current and Emerging Role of Radiogenomics in Risk Assessment.” October 2020. Accessed Apr 2024. https://grandroundsinurology.com/current-and-emerging-role-of-radiogenomics-for-prostate-cancer/
Current and Emerging Role of Radiogenomics in Risk Assessment – Summary
John Feller, MD, Founding Partner and Medical Director of Desert Medical Imaging, Assistant Clinical Professor in the Departments of Radiology at Loma Linda University and at Riverside School of Medicine, Chief of Radiology and Partner of the American Medical Center in China reviews data for evaluating radiogenomics in terms of risk stratification for focal therapy and for developing novel combination therapies. Dr. Feller introduces a phase II study on laser focal therapy of prostate cancer and another study on the Decipher Genomics Resource Information Database (GRID) from which much of the data he discusses originates. He then discusses a phase II clinical trial on outpatient trans-rectal MR-guided Laser Focal Therapy that found that short-term and intermediate-term oncologic control achievable in 79% of patients with initial treatment. Dr. Feller then discusses the ability of responders to focal therapy to be distinguished from non-responders with support from findings showing lower PSA values and lower PSA density in responders as opposed to nonresponders. He continues with an overview of the Decipher GRID data from HALO Dx, an advanced diagnostics and treatment solutions company, revealing that genes can be used to differentiate responders from non-responders. He concludes that MpMRI followed by genomics shows promise for risk stratification for focal therapy and that multiple complex data sources present an opportunity for artificial intelligence before giving a quick presentation on machine learning algorithms.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and become seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. For more educational activities from this virtual event, visit our collection page.
